Learn more about our superior nicotine gum and how it is adapted to fit a market with huge potential.
Realize the benefits of our technology for development of active gums.
Learn more about how to become a partner and what´s in our pipeline.
The supplements was minor editorial changes and Enorama now enters the final stage of the MAA process.
Enorama Pharma believes that there will be a great need for serious cannabis products in the future.
Micael Karlsson, lawyer and partner at lawfirm Delphi, explains.
This decision does not affect Enorama Pharma's ongoing development work in India.
Enorama Pharma travels to Athens to meet several potential customers.
Two extremely meritorious contributions to Enorama Pharma's Board of Directors.
Enorama initiates a collaboration with Dr. Hazekamp to benefit from his expertise within cannabis.
MJBizDaily’s European Cannabis Symposium gathers leaders within Europe’s medical cannabis markets.
Enorama's new unit for nicotine products, non-pharmaceuticals, works with oral nicotine.
These applications are a first step towards the approval of the products in the EU.
The Company establishes a development laboratory at Malmö University's Open Lab, Sweden.
In February 2019, Enorama Pharma entered into an agreement with the company MediiGum LLC.
The permit means that the Company can now begin developing a chewing gum with medical cannabis.
152%! We reached our goal with good margin. The preferential rights issue oversubscribed.
Enorama now has all the approvals required to apply for registration of medical products in Europe.